Sandoz announced today that it has enrolled its first patient in a combined phase 1 and phase 3 study of its proposed denosumab biosimilar versus EU-authorized Prolia.
Sandoz announced today that it has enrolled its first patient in a combined phase 1 and phase 3 study of its proposed denosumab biosimilar versus EU-authorized Prolia.
Denosumab, a monoclonal antibody that inhibits the RANKL protein and thereby decreases the production of osteoclasts, is indicated for a number of conditions, including osteoporosis in postmenopausal women, increased fracture risk in men, a treatment-induced bone loss, among others.
“People with the bone disease osteoporosis are more likely to fracture or break a bone, causing pain and restriction of mobility, which can be extremely debilitating,” said Florian Bieber, global head of development at Sandoz, in a statement announcing the trial. “As we progress our development program for proposed biosimilar denosumab, we believe it gives patients hope for early and expanded access to advanced biologic medicines, which may change the course of their disease.”
The study, ROSALIA, is a multicenter, randomized, parallel-arm, double-blind study with a total duration of up to 82 weeks. The drug maker plans to enroll approximately 522 postmenopausal patients with osteoporosis for 2 treatment periods.
In the first period of 52 weeks, patients will be randomized to receive 2 doses of either GP2411 or the EU-authorized reference product.
In the second treatment period, from week 52 to week 78, patients who received the reference denosumab in the first period will be rerandomized either to continue to receive the reference or to switch to GP2411. All patients in the biosimilar group will continue with a third dose of GP2411.
The study’s primary end points include percentage change in lumbar spine bone mineral density, and the drug maker expects to complete the study by June 2022.
The reference drug, Prolia, has been a strong seller for Amgen, the innovator behind denosumab. In first quarter 2019 financial results, Amgen said that the drug had brought in $390 million in the United States and $202 million in the rest of the world. Those sales were up 20% year over year, said the company, driven by higher unit demand.
Other biosimilar developers targeting denosumab include Australian drug maker NeuClone; the company announced in early 2018 that it had entered early-stage development of a proposed biosimilar.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.